Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Research groups

Susan Morris



Gilbert Group


The main focus of my research is to generate Simian adenoviral vectored vaccines for a range of emerging and re-emerging pathogens including SARS CoV-2. Emerging pathogen outbreaks require a quick and efficient response. Manufacturing methods for Adenovirus vectors at large scale have been developed, however the process from selecting an antigen to starting a clinical trial takes at least 18 months, which has ruled out the current manufacturing technology in the event of a pandemic. I have been working on improving the manufacturing processes for Adenovirus vaccines to minimise the time required from concept to end product. I work closely with the Clinical Biomanufacturing facility to ensure all processes are transferable to a GMP environment.

Another aspect of my research is the design and development of new viral vectors.


Recent publications

More publications